Esomeprazole Magnesium Trihydrate Cas:217087-09-7

We are Esomeprazole Magnesium Trihydrate CAS:217087-09-7 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Product Description:

Product Name: Esomeprazole magnesium trihydrate CAS NO: 217087-09-7                                 

                    

Synonyms:

Esomeprazole magnesium;

(S)-Omeprazole magnesium trihydrate;

5-methoxy-2-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylsulfinyl]benzimidazol-1-ide;

 

Chemical & Physical Properties:

Appearance: Off-white powder

Assay :≥99.0%

Boiling Point: 600℃ at 760 mmHg

Melting Point: 184-189℃ (dec.)

Flash Point: 316.7℃

Vapor Pressure: 2.35E-14mmHg at 25℃

StorageTemp: -20℃ Freezer

Solubility: Slightly soluble in water, soluble in methanol, practically insoluble in heptane.     

 

Safety Information:

Hazard Code:  Xn

Risk Statements: R22

WGK Germany: 3

HS Code:  2933399090

 

S-Form of Omeprazole. Gastric proton-pump inhibitor.

esomeprazole magnesium trihydrate for the healing of peptic ulcers associated with non-steroidal anti-inflammatory drug NSAID (non-selective and COX-2 selective) therapy.

Zollinger-Ellison syndrome

Peptic ulcer, site unspecified

Duodenal ulcer

Gastric ulcer

Gastro-oesophageal reflux disease

Esomeprazole belongs to the family of medications known as proton pump inhibitors (PPIs). Esomeprazole is registered by the Therapeutic Goods Administration (TGA) for the following indications:

Gastro-Oesophageal Reflux Disease (GORD):

treatment of erosive reflux oesophagitis;

long-term management of patients with healed oesophagitis to prevent relapse;

symptomatic treatment of gastro-oesophageal reflux disease (GORD).

In combination with appropriate antibiotics for:

healing of duodenal ulcer associated with Helicobacter pylori;

eradication of Helicobacter pylori in patients with active or healed peptic ulcer.

Short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug (NSAID) (non-selective and COX-2 selective) therapy.

Healing of gastric ulcers associated with non-steroidal anti-inflammatory drug NSAID (non-selective and COX-2 selective) therapy.

Prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug NSAID (non-selective and COX-2 selective) therapy in patients at risk.

 

If you are interested in our products or have any questions, please feel free to contact us!

 

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.

Related Products:N-(3-anilino-5-methylsulfanyl-[1,2,4]triazol-4-yl)-N’,N’-diphenyl-guanidine manufacturer | 2-(5-(hydroxy-24-trioxidaneyl)-13,34,43,54-pentaoxol-3-yl)-6-tetraoxidaneyl-24,33,44,53,64,73,83,94-pentaoxolo[2,1]hexaoxine supplier | (2-hydroxy-2-oxido-1,3,2-dioxaphospholan-4-yl)methyl palmitate producer.